Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.40 |
| ▸ | DRD2 | P14416 | 9/20 | 0.35 |
| ▸ | DRD3 | P35462 | 9/20 | 0.35 |
| ▸ | DRD4 | P21917 | 4/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
| ▸ | DRD5 | P21918 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8622286 | 0.90 | HTR1A (0.38) | DRD2DRD3HTR1AHTR7CHRM3 | |
| SCHEMBL8619777 | 0.83 | DRD2 (0.36) | DRD2DRD3DRD4HTR1ADRD1 | |
| SCHEMBL8624076 | 0.74 | CHRM3 (0.38) | DRD2DRD3HTR1AHTR7CHRM2 | |
| Tramazoline SCHEMBL8623881 | 0.72 | BCL2L1 (0.47) | — | |
| SCHEMBL13448455 | 0.71 | CYP19A1 (0.41) | CYP19A1DRD2DRD3DRD4HTR1A | |
| SCHEMBL8625063 | 0.71 | MTNR1A (0.30) | — | |
| SCHEMBL8622487 | 0.71 | SIGMAR1 (0.32) | HTR1A | |
| SCHEMBL599314 | 0.66 | CYP19A1 (0.54) | CYP19A1HTR1A | |
| SCHEMBL8627077 | 0.66 | HTR2C (0.35) | HTR1A | |
| SCHEMBL20131348 | 0.66 | HTR7 (0.63) | DRD2DRD3HTR1AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5708015-A | SENSITIVE ALPHA 2 ADRENERGIC RECEPTORS | ALLERGAN (US) | 1998-01-13 | — | — | US | disclosed |
| US-5580892-A | ANTIDIARRHETIC, ANTISPASTIC, ANTIEPILEPTIC AGENTS; DIURETICS | ALLERGAN | 1996-12-03 | — | — | US | disclosed |
| EP-0724439-A1 | USE OF 2-(2-ALKYLPHENYLAMINO)-OXAZOLINES, -THIAZOLINES AND -IMIDAZOLINES AS ALPHA 2 ADRENERGIC AGENTS | Allergan (US) | 1996-08-07 | — | — | EP | disclosed |
| WO-1995011021-A1 | USE OF 2-(2-ALKYLPHENYLAMINO)-OXAZOLINES, -THIAZOLINES AND -IMIDAZOLINES AS ALPHA 2 ADRENERGIC AGENTS | ALLERGAN (US) | 1995-04-27 | — | — | WO | disclosed |
| US-5252595-A | Method for reducing or maintaining intraocular pressure in the mammalian eye by administering pharmaceutical compositions containing 2-(2-alkylphenylamino)-oxazolines, 2-(2-alkylphenylamino)-thiazolines and 2-(2-alkylphenylamino)-imidazolines | ALLERGAN, INC. (US) | 1993-10-12 | — | — | US | disclosed |